PureTech Well being spinout Celea Therapeutics will apply the financing towards a Section 3 check of its idiopathic pulmonary (IPF) drug, deupirfenidone. The pivotal examine will check the oral small molecule head-to-head in opposition to a typical of care IPF drug.
The submit Lung-Targeted Celea Secures $180M for Pivotal Check of Pulmonary Fibrosis Drug appeared first on MedCity Information.
